In my role as Chief Medical Officer, I lead patient safety and quality assurance teams for our portfolio of medicines – from investigational new drug phase to established products. I am responsible for the overall benefit risk assessment of our medicines and guide our global regulatory policy and intelligence.

My passion for excellence in clinical investigation has been honed by more than 30 years as a researcher, with an extensive background in Phase 1 and 2 clinical trial design and execution, portfolio strategy, clinical operations, data management, compliance, safety reviews, global health and project management. My pharmaceutical leadership experience in exploratory research and early clinical development followed 15 years of clinical research, teaching, and practicing medicine at Massachusetts General Hospital, where I also co-led a clinical research training program for medical students and residents. 

Through my rewarding roles as a physician, educator and scientist, I’ve gained deep appreciation for the needs of patients and value their insights as we continually strive to offer them life-changing medicines.

I have authored and co-authored 48 peer-reviewed papers, 27 book chapters and reviews, and served on the editorial board of the Journal of Clinical Endocrinology and Metabolism. I am a member of several scientific and medical societies including the American Medical Society, American Federation for Medical Research and the Endocrine Society.

Board certified in endocrinology, I earned a medical degree from Harvard Medical School. I completed an internship and residency in Internal Medicine, and a fellowship in Endocrinology and Metabolism at Massachusetts General Hospital before joining the faculty there. My research in the Reproductive Endocrine Unit at Mass General focused on the physiology of female reproductive disorders.

I am passionate about bringing the patient voice to everything we do at AstraZeneca. Understanding the patient experience is what has guided me as a practicing physician, in teaching medicine and in my 35 years in exploratory research and early clinical development.

Ann E. Taylor Chief Medical Officer


Chief Medical Officer


Led the clinical development organization of Medimmune, the biologics research and development division of AstraZeneca, from preclinical to Phase 2b, including clinicians, clinical scientists, operations, biometrics, medical communications and quality assurance organizations


Held increasing levels of responsibility at Novartis Institutes for BioMedical Research (NIBR), most recently as Vice President and Global Head, Program Office Co-led the CVM Disease Area Decision Board and collaborated with colleagues on research strategies from early compounds to clinical profiling of later-stage compounds


Guided cardiovascular and metabolic (CVM) disease clinical research for Pfizer, most recently as Director, Early Clinical Portfolio Lead for Obesity and Frailty, Global Research and Development.

High-quality triplicate electrocardiogram monitoring in a first-in-man study: potential for early detection of drug induced QT prolongation

He YL, Zhang Y, Yan JH, Zhou W, Komjathy S, Taylor A. Int J Clin Pharmacol Ther. 2013 Dec;51(12):948-57.


Polycystic Ovarian Syndrome. In Primary Care of Women

Taylor AE. Polycystic Ovary Syndrome. In Primary Care of Women, Second Edition. Carlson KJ, Eisenstat SA, Frigoletto FD Jr, Schiff I (Eds.), Mosby-Yearbook Publishers, St. Louis, 2002


An instrument for determining the amount of NIH support for clinical investigations at one academic health center

Taylor AE. Stubbs C, Singer DE, Curhan G, Crowley WF Jr. Acad Med. 2002 Aug;77(8):824-30.

Hyperandrogenic Disorders. In Kistner’s Gynecology and Women’s Health

Taylor AE and Dunaif AE. Hyperandrogenic Disorders. In Kistner’s Gynecology and Women’s Health, Seventh Edition. Barbieri RL, Ryan KJ, Dunaif AE (Eds.), Mosby, United Kingdom, 1999

Impact of binge eating on metabolic and leptin dynamics in normal young women

Taylor AE, Hubbard J, Anderson EA. J Clin Endocrinol Metab. 1999 Feb;84(2):428-34.


Understanding the underlying metabolic abnormalities of Polycystic Ovary Syndrome and their implications

Taylor AE. Am J Ob Gyn. 1998 Dec;179(6 Pt 2):S94-S100.